

04-Apr-2024

Valproate - containing medicines: new measures regarding the potential risk of neurodevelopmental disorders in children of fathers treated with valproate in the 3 months prior to conception

Dear Healthcare professional,

SANOFI Saudi Arabia in agreement with the Saudi Food and Drug Authority (SFDA) would like to inform you of the following:

Summary

- **A retrospective observational study in 3 Nordic countries suggests an increased risk of neurodevelopmental disorders (NDDs) in children (from 0 to 11 years old) born to men treated with valproate as monotherapy in the 3 months prior to conception compared to those born to men treated with lamotrigine or levetiracetam as monotherapy. Due to study limitation, this risk is possible but is not confirmed.**

New measures for valproate use in male patients

- **It is recommended that in male patients valproate is initiated and supervised by a specialist experienced in treatment of epilepsy.**
- **Prescribers should inform male patients about the potential risk and discuss with them the need to consider effective contraception, including for a female partner, while using valproate and for 3 months after stopping the treatment;**
- **Treatment with valproate in male patients should be regularly reviewed by prescribers to evaluate whether valproate remains the most suitable treatment for the patient.**
- **For male patients planning to conceive a child, suitable alternative treatment options should be considered and discussed with the patient. Individual circumstances should be evaluated for each patient. It is recommended that advice from a specialist experienced in the management of epilepsy should be sought as appropriate.**
- **The male patients should be advised to not donate sperm during treatment and for at least 3 months after treatment discontinuation.**
- **A patient guide should be provided to male patients.**

Background on the safety concern

The evaluation of data from a study (EUPAS32401) conducted by pharmaceutical companies of valproate-containing products as an obligation in the European Union was carried out. The primary objective was to investigate the risk of neurodevelopmental disorders in offspring paternally exposed to valproate as monotherapy, compared to lamotrigine or levetiracetam as monotherapy treatment, in the 3 months period prior to conception. This retrospective observational study was conducted using data from multiple registry databases in Denmark, Sweden and Norway. The primary outcome of interest

was NDDs (composite endpoint including autism spectrum disorders, intellectual disability, communication disorders, attention deficit/hyperactivity disorders, movement disorders) in offspring up to 11 years of age. The mean follow-up time of children in the valproate group ranged between 5.0 and 9.2 years compared to 4.8 and 6.6 years for children in the lamotrigine/levetiracetam group.

- The meta-analysis of data from the 3 countries resulted in a pooled adjusted hazard ratio (HR) of 1.50 (95% CI: 1.09-2.07) for NDDs in children from fathers treated with valproate monotherapy in the 3 months prior to conception compared to the composite lamotrigine/levetiracetam monotherapy group.
- The adjusted cumulative risk of NDDs ranged between 4.0% to 5.6% in the valproate group monotherapy versus between 2.3% to 3.2% in the composite lamotrigine/levetiracetam monotherapy group.

The study was not large enough to investigate associations with specific NDD subtypes. Due to study limitations, including potential confounding by indication and differences in follow-up time between exposure groups, the risk of NDDs in children of fathers that used valproate in the 3 months prior to conception is considered a potential risk and a causal association with valproate is not confirmed.

The study did not evaluate the risk of NDD to children born to men who had discontinued valproate treatment for more than 3 months before conception (i.e., allowing a new spermatogenesis without valproate exposure).

The observed potential risk of NDDs after paternal exposure in the 3 months before conception is of lower magnitude than the known risk for NDDs after maternal exposure during pregnancy. When valproate is administered as monotherapy to women, studies in pre-school children exposed in utero to valproate show that up to 30-40% experience delays in their early development such as talking and walking later, lower intellectual abilities, poor language skills (speaking and understanding) and memory problems.

Based on the available data, new measures for valproate use in men have been adopted as specified in the "summary" above. The product information of all valproate-containing medicines is being updated to inform healthcare professionals and patients of the potential risk of NDD in children of men treated with valproate and to provide guidance regarding use of valproate in men. In addition, educational materials will be available for healthcare professionals and male patients. These include:

- An updated guide for healthcare professionals with a dedicated section on the use of valproate in male patients;
- A new patient guide for males, which should be provided to male patients using valproate;
- An update of the existing patient card with the information for male patients, included in or attached to the outer packaging, so that it will be provided in the pharmacy to the patient each time the medicine is dispensed.

Call for reporting

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to:

National Pharmacovigilance Center at the SFDA.

Website: <https://ade.sfda.gov.sa/>

E-mail: npc.drug@sfda.gov.sa

Phone: 1999

Fax: +966-11-2057662

SANOFI contact point:

SANOFI Saudi Arabia Pharmacovigilance Center contact information:

Email: Ksa_pharmacovigilance@sanofi.com

Mobile: + 966-54-428-4797

For Medical Information enquiries, please contact:

Phone: +966 12 669 3318 | **Email:** ksa.medicalinformation@sanofi.com

Mossab Shafy

Country Safety Head & Local QPPV